Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study

Inclusion Criteria: * Male or female ≥ 18 and ≤ 75 years * Patient expressing the HLA-A\*0201 subtype of the human leukocyte antigen (HLA -A2) * Patient with metastatic melanoma stage IIIc or IV (AJCC 2010) except brain metastases * Tumor expressing the antigens Melan-A and MELOE-1 detected by RT-PCR * Absence of cerebral metastases * ECOG ≤ 1 or Karnofsky ≥ 80% * Prior adjuvant melanoma treatment (before metastatic stage) authorized (anti- BRAF, anti-CTLA4, IFN, TIL... ) * Disease measurable / evaluable within 28 days before the first administration of study treatment * Negative viral serology (HIV 1/2, Ag p24 , HTLV 1/2 , hepatitis B and C, syphilis) * Results of analysis: * Hemoglobin ≥ 10 g / dl or ≥ 6.25 mmol / l * Leukocytes ≥ 4000/μl * Lymphocytes ≥ 1500/μl * Platelets ≥ 80.000/μl * Creatinine ≤ 2.5 N * Total bilirubin ≤ 3 N * AST and ALT ≤ 3 N without liver metastases; ≤ 5 N with liver metastases * Negative pregnancy test for women of childbearing age * Patient affiliated to a social security system * Patient who has signed informed consent Exclusion Criteria: * Brain metastases * Ocular primitive melanoma * Treatment of metastatic melanoma by more than two lines (chemotherapy , immunotherapy, targeted therapy or radiotherapy) or within 4 weeks before the inclusion * Treatment with ipilimumab within 8 weeks before the inclusion * Known allergy to albumin * Contraindication to the use of vasopressors * Positive viral serology for HIV 1/2 , Ag p24 , HTLV 1/2, hepatitis B or C, or syphilis * Women who are pregnant, nursing or refusing to use contraceptives, women with no negative pregnancy test at baseline * Presence of a second active cancer (with the exception of cervical cancer in situ or skin cancer other than melanoma) * History of event or current event of a progressive or non-stabilized severe heart disease (congestive heart failure, coronary artery disease, uncontrolled hypertension, serious arrhythmias or ECG signs of previous myocardial infarction) * Uncontrolled thyroid dysfunction * Any serious acute or chronic illness (active infection requiring antibiotics, bleeding disorders or other condition requiring concomitant treatment not allowed in this study) * History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, ... ) with the exception of patients with active vitiligo or a history of vitiligo * History of uveitis and retinopathy associated with melanoma * Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")